Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $555
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $540 to $555.
June 24, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $540 to $555.
The raised price target and maintained Overweight rating from a reputable analyst at Wells Fargo is likely to positively impact Vertex Pharmaceuticals' stock price in the short term. Investors often view such updates as a strong buy signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100